Theratechnologies (TSE:TH) has released an update.
Theratechnologies Inc. has announced a strategic shift to ramp up its commercial operations, while winding down preclinical oncology research. The company will focus on advancing its Phase 1 clinical trial for sudocetaxel zendusortide in advanced ovarian cancer patients and is actively seeking partners to further its R&D. They expect to incur restructuring charges in 2024 but aim to optimize costs and achieve positive Adjusted EBITDA.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
